Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02328547 · ClinicalTrials.gov registry record · Phase 2
Fecal Microbiota Transplantation for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome
A Phase 2 study, sponsored by Montefiore Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
NCT02328547 is a Phase 2 study that has completed, run by Montefiore Medical Center. The registered enrollment target is 48 participants.
The verdict
NCT02328547, a Phase 2 study, has completed, sponsored by Montefiore Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
Study Summary
The objectives of this study are (1) to determine the efficacy of fecal microbiota transplantation (FMT), given as oral capsules, compared with placebo for the treatment of refractory diarrhea-predominant irritable bowel syndrome (IBS-D); (2) determine the impact of FMT on the intestinal microbiome of patients with IBS-D; and (3) assess the safety, feasibility, and tolerability of FMT for patients with IBS-D.
Interventions
- DRUG Placebo capsules
- DRUG Fecal microbiota transplantation capsules
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2015-05 |
| Est. Completion | 2018-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02328547
The ClinicalTrials.gov registry entry for NCT02328547 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Montefiore Medical Center, which has 345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo capsules is the first listed.
NCT02328547 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02328547 about?
NCT02328547 is a clinical study titled "Fecal Microbiota Transplantation for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome". The objectives of this study are (1) to determine the efficacy of fecal microbiota transplantation (FMT), given as oral capsules, compared with placebo for the treatment of refractory diarrhea-predominant irritable bowel syndrome (IBS-D); (2) determine the impact of FMT on the intestinal microbiome ...
What is the current status of trial NCT02328547?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2015-05. Estimated completion is 2018-03.
What interventions are being tested in trial NCT02328547?
The interventions under investigation include: Placebo capsules (DRUG), Fecal microbiota transplantation capsules (DRUG).
Who is sponsoring clinical trial NCT02328547?
This trial is sponsored by Montefiore Medical Center, which has 345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.